CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	286.5	298.26	389.48	211.89	923.03	1,169
Short-Term Investments	1,629	1,606	1,304	1,603	1,456	521.71
Cash & Short-Term Investments	1,916	1,904	1,694	1,815	2,379	1,690
Cash Growth	-1.03%	12.41%	-6.70%	-23.70%	40.75%	79.10%
Accounts Receivable	-	25	200	-	0.31	0.14
Other Receivables	-	2.1	6.5	11.2	8.4	10.7
Receivables	-	27.1	206.5	11.2	8.71	10.84
Prepaid Expenses	9.88	6.21	7.89	26.01	29.68	15.44
Restricted Cash	3.5	-	-	0.5	-	-
Total Current Assets	1,929	1,937	1,908	1,853	2,418	1,717
Property, Plant & Equipment	255.49	277.55	305.94	320.56	312.04	93.03
Long-Term Investments	51.01	-	1.97	53.13	-	-
Other Intangible Assets	-	-	0.02	0.07	0.13	0.18
Other Long-Term Assets	9.71	27.35	13.57	16.28	22.2	18.14
Total Assets	2,245	2,242	2,230	2,243	2,752	1,828
Accounts Payable	11.8	14.71	38.15	27.43	14.82	9.09
Accrued Expenses	24.9	39.41	40.67	61.33	77.77	54.32
Current Portion of Leases	18.26	17.29	15.63	15.84	12.16	11.36
Current Income Taxes Payable	3.43	0.45	0.44	0.14	0.72	10.47
Current Unearned Revenue	1.3	3.85	4.11	-	1.01	2.34
Other Current Liabilities	59.28	12.08	9.81	16.38	13.4	6.67
Total Current Liabilities	118.96	87.78	108.79	121.11	119.88	94.26
Long-Term Leases	192.77	206.41	223.01	228.18	212.87	50.07
Long-Term Unearned Revenue	12.32	12.32	14.01	12.32	12.32	11.78
Other Long-Term Liabilities	5.28	3.44	0.96	5.97	7.34	7.63
Total Liabilities	329.33	309.95	346.77	367.58	352.42	163.73
Common Stock	3.01	2.7	2.5	2.44	2.39	2.28
Additional Paid-In Capital	3,725	3,294	2,878	2,735	2,598	2,236
Retained Earnings	-1,817	-1,366	-999.7	-846.09	-195.92	-573.58
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	4.99	1.84	1.91	-15.65	-5.07	-0.08
Total Common Equity	1,916	1,932	1,883	1,875	2,399	1,664
Shareholders' Equity	1,916	1,932	1,883	1,875	2,399	1,664
Total Liabilities & Equity	2,245	2,242	2,230	2,243	2,752	1,828
Total Debt	211.02	223.69	238.63	244.02	225.03	61.43
Net Cash (Debt)	1,733	1,680	1,457	1,624	2,154	1,629
Net Cash Growth	1.46%	15.31%	-10.30%	-24.59%	32.24%	82.77%
Net Cash Per Share	19.82	19.92	18.39	20.89	26.79	24.70
Filing Date Shares Outstanding	95.3	85.77	80.28	78.65	77.07	75.43
Total Common Shares Outstanding	93.87	85.74	80.04	78.51	76.99	73.91
Working Capital	1,810	1,849	1,799	1,732	2,298	1,622
Book Value Per Share	20.41	22.53	23.52	23.89	31.17	22.52
Tangible Book Value	1,916	1,932	1,883	1,875	2,399	1,664
Tangible Book Value Per Share	20.41	22.53	23.52	23.89	31.16	22.51
Machinery	54.8	54.4	53.26	49.62	36.25	29.5
Construction In Progress	5.8	6.12	8.86	6.16	52.4	8.37
Leasehold Improvements	145.85	145.85	143.26	141.68	86.74	25.47

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q